Basic Information
NEX-I Develops New Generation Therapy for Immunotherapy-Resistant Cancers, Achieving Breakthrough Progress in Cancer TreatmentNEX-I has achieved breakthrough progress in the field of cancer treatment by developing a new generation of therapies aimed at cancers resistant to immunotherapy. Utilizing its proprietary platform, NEX-I has created robust models of immunotherapy-refractory cancers to analyze their characteristics and comprehensively identify novel therapeutic targets. This unique and focused research has uncovered a series of soluble targets—ONCOKINE—through a proprietary screening platform, which are highly expressed and play a critical role in refractory cellular mechanisms. NEX-I proposes an entirely new standardized solution to inhibit cancer cell growth and metastasis.